Ranibizumab biosimilar - Formycon/Bioeq

Drug Profile

Ranibizumab biosimilar - Formycon/Bioeq

Alternative Names: FYB201

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Formycon
  • Developer Bioeq; Formycon
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wet age-related macular degeneration

Most Recent Events

  • 25 Jul 2016 9199913- No relevant info to update
  • 19 May 2016 Santo Holding/bioeq in-licenses ranibizumab from Formycon
  • 19 May 2016 Formycon initiates enrolment in a phase III trial for Wet age-related macular degeneration (NCT02611778)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top